Publications
CERE-120 References
Parkinson's Disease:
Bartus RT, Herzog CD, Bishop K, Ostrove JM, Tuszynski M, Kordower JH, Gasmi M. Issues regarding gene therapy products for Parkinson's disease: the development of CERE-120 (AAV-NTN) as one reference point.
Parkinsonism Relat Disord. 2007;13 Suppl 3:S469-77.
View article
Herzog CD, Brown L, Gammon D, Kruegel B, Lin R, Wilson A, Bolton A, Printz M, Gasmi M, Bishop KM, Kordower JH, Bartus RT. Expression, bioactivity, and safety 1 year after adeno-associated viral vector type 2-mediated delivery of neurturin to the monkey nigrostriatal system support cere-120 for Parkinson's disease.
Neurosurgery. 2009 Apr;64(4):602-12;
View article
Herzog CD, Dass B, Gasmi M, Bakay R, Stansell JE, Tuszynski M, Bankiewicz K, Chen EY, Chu Y, Bishop K, Kordower JH, Bartus RT. Transgene expression, bioactivity, and safety of CERE-120 (AAV2-neurturin) following delivery to the monkey striatum.
Mol Ther. 2008 Oct;16(10):1737-44.
View article
Marks W.J., Ostrem J.L., Verhagen L., Starr P.A., Larson P.S., Bakay R.A.E., Taylor R., Cahn-Weiner D.A., Stoessl A.J., Olanow C.W., Bartus R.T. Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson’s disease: an open-label, phase I trial.
Lancet Neurol, May 2008, 7:400-08
Herzog C.D., Dass B., Holden J.E., Stansell J., Gasmi M, Tuszynski M. Bartus R.T., Kordower J.H. Striatal delivery of CERE-120, an AAV2 vector encoding human neurturin, enhances activity of the dopaminergic nigrostriatal system in aged monkeys.
Movement Disorders, 2007, 22, 1124-1132
Gasmi M., Brandon E.P., Herzog C.D., Wilson A., Bishop K.M, Hofer E.K., Cunningham J.J., Printz M.A., Kordower J.H., Bartus RT. AAV2-mediated delivery of human neurturin to the rat nigrostriatal system: long-term efficacy and tolerability of CERE-120 for Parkinson’s disease.
Neurobiology of Disease, 2007,27, 67-76.
Gasmi M., Herzog C.D., Brandon E.P., Cunningham J.J., Ramirez G.A., Ketchum E.T., and Bartus R.T. Striatal delivery of neurturin by CERE-120, an AAV2 vector for the treatment of dopaminergic neuron degeneration in Parkinson’s disease.
Molecular Therapy, 2007, 15, 62-68.
Kordower J.H., Herzog C.D., Dass B., Bakay R.A.E., Stansell J., Gasmi M., Bartus R.T. Delivery of neurturin by AAV2 (CERE-120) mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP-treated monkeys.
Annals of Neurology, 2006, 60, 706-715.
Huntington's Disease:
Ramaswamy S., McBride JL, Han I, Berry-Kravis EM, Zhou L, Herzog CD, Gasmi M, Bartus RT, Kordower JH. Intrastriatal CERE-120 (AAV-Neurturin) protects striatal and cortical neurons and delays motor deficits in a transgenic mouse model of Huntington's disease.
Neurobiol Dis. 2009 Apr;34(1):40-50.
Visit article
Ramaswamy S., McBride J., Herzog C.D., Brandon E., Gasmi M., Bartus R.T., and Kordower J.H. Neurturin gene therapy improves motor function and prevents death of striatal neurons in a 3-nitropropionic acid rat model of Huntington’s disease.
Neurobiology of Disease, 2007, 26, 375-84.
McBride J.L., Ramaswamy S., Gasmi M., Bartus R.T., Herzog C.D., Brandon E.P., Zhou L., Pitzer M.R., Berry-Kravis E.M. and Kordower J.H. Viral delivery of glial cell line-derived neurotrophic factor improves behavior and protects striatal neurons in a mouse model of Huntington’s disease.
Proceedings of the National Academy of Sciences, 2006, 103, 9345-50.
Alzheimer's Disease:
Bishop KM, Hofer EK, Mehta A, Ramirez A, Sun L, Tuszynski M, Bartus RT. Therapeutic potential of CERE-110 (AAV2-NGF): targeted, stable, and sustained NGF delivery and trophic activity on rodent basal forebrain cholinergic neurons.
Exp Neurol. 2008 Jun;211(2):574-84.
Visit article
Clinical Abstracts
CERE-110 for Alzheimer's Disease
Zoe Arvanitakis, Mark H. Tuszynski, Steven Potkin, Raymond Bartus, David Bennett. A Phase 1 Clinical Trial of CERE-110 (AAV-NGF ) Gene Delivery in Alzheimer’s Disease.
American Academy of Neurology Annual Meeting, Boston, MA, May 2007.
CERE-120 for Parkinson's Disease
William J. Marks, Jr., Jill L. Ostrem, Leonard Verhagen, Philip A. Starr, Paul S. Larson, Roy A. E. Bakay, C. Warren Olanow, and Raymond T. Bartus. AAV2-Neurturin (CERE-120) for Parkinson's Disease: 24-Month Follow-Up from the Phase I Clinical Trial.
The Movement Disorder Society Conference. Chicago, IL, June, 2008
Philip A. Starr, Leo Verhagen Metman, Paul S. Larson, Roy A. Bakay, Robin Taylor, Deborah Cahn-Weiner, Raymond T. Bartus, Jill L. Ostrem, William J. Marks, Jr. Intrastriatal gene transfer with AAV-neurturin for Parkinson’s disease: results of a phase I trial.
American Association of Neurological Surgeons Annual Meeting, San Francisco, CA, April 2007.
William J. Marks, Jr., Leo Verhagen Metman, Philip A. Starr, Paul S. Larson, Roy A. Bakay, Robin Taylor, Daniel R. Lee, Raymond T. Bartus, Jill L. Ostrem. Neurturin gene transfer for Parkinson’s disease: motor outcomes from the initial CERE-120 clinical trial.
Movement Disorders Society Annual Meeting, Kyoto, Japan, November 2006.
William J. Marks, Jr., Leo Verhagen Metman, Philip A. Starr, Paul S. Larson, Roy A. Bakay, Robin Taylor, Daniel R. Lee, Deborah Cahn-Weiner, Raymond T. Bartus, Jill L. Ostrem. Trophic Factor Gene Transfer in Parkinson's Disease: Preliminary Outcomes from the Phase I CERE-120 Study.
American Neurological Association 131st Annual Meeting, Chicago, IL, October 2006,
William J. Marks, Jr., Leonard A. Verhagen Metman, Philip A. Starr, Paul S. Larson, Roy A. Bakay, Robin Taylor, Deborah Cahn-Weiner, Raymond T. Bartus, Jill L. Ostrem. Phase I Study of Putaminal Gene Transfer with Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN] (CERE-120) for Parkinson
s Disease: Preliminary Observations.
American Academy of Neurology Annual Meeting, San Diego, CA, April 2006.